Gold Sponsor
Polyplus
Polyplus-transfection® SA is a biotechnology company that develops and sells innovative solutions for the delivery of nucleic acids in research, bioproduction and therapeutics. Located close to the University of Strasbourg in Eastern France, Polyplus-transfection® is ISO 9001-certified since 2002 and supplies its wide range of reagents for the transfection of genes, oligonucleotides and siRNA through a worldwide distributor network. Polyplus-transfection® reagents are involved in a growing number of clinical trials worldwide. In addition, Polyplus-transfection® holds a broad estate of patents and licenses including original methods for therapeutic siRNA delivery.
Associated Experts
Job Title: Scientific Communication Specialist
Job Title: Scientific Support Specialist
Job Title: Business Manager EMEA
Job Title: Research Assistant in R&D Bioproduction
Job Title: Bioproduction Project Leader
Job Title: CSO
Job Title: in vivo project leader
Associated Content
Innovative Solutions for mRNA Vaccine Manufacturing: A Practical Guide Using PolyPlus LipidBrick® and Services
Lipid nanoparticles (LNPs) play a crucial role in the development and manufacturing of DNA and RNA therapeutics including the Pfizer-BioNTech and Moderna messenger RNA (mRNA)-based COVID-19 vaccines. LNPs serve as non-viral delivery vehicles that encapsulate ... Continued
Industrial Scale Manufacturing of AAV: A Blueprint
The successful commercialization of adeno-associated viral vectors (AAV) relies on GMP-compliant and scalable, industrialized production platforms to rapidly advance high-quality products to market while also ensuring patient safety. The most utilized approach to AAV production ... Continued
Polyplus FectoVIR®-AAV GMP Enables Large Scale AAV Transient Transfection
A highly effective transient transfection reagent that can be used to produce high-quality, regulatory compliant therapeutic viral vectors for patient administration. The field of cell and gene therapy is expanding rapidly, which has increased the demand ... Continued
In vivo-jetRNA® as a promising tool for RNA therapeutics
Nucleic acid-based vaccination is a promising technology that is particularly attractive to prevent or treat infectious diseases and cancer. A nucleic acid vaccine consists of a genetic sequence that is administered in vivo to be taken up by cells that will express at their cell surface or secrete the encoded antigen for induction of an immune response. Main technical challenges associated with the use of nucleic acid vaccines are efficacy and safety. To address these challenges, it is important to take into account the following parameters during initial research development of a genetic vaccine: the type of nucleic acid used and the delivery method....Continued
Improving expression and purification of mAb using FectoCHO® Expression System and MabXpure™
INTRODUCTION Transient gene expression (TGE) is commonly used for medium scale production of recombinant proteins and antibodies in suspension CHO cell lines. This approach allows production of sufficient protein amounts for “proof of concept” studies or ... Continued
Improved Protein yields in CHO and HEK293 cells using a dedicated transfection reagent: FectoPRO®
Jelena Vjetrovic1, Valérie Kedinger1, Raphaël Hopfner2, Philippe Funfrock2 Introduction Transient gene expression (TGE) is commonly used for medium scale production of recombinant proteins and antibodies. This approach allows generation of sufficient protein amounts without an investment in ... Continued
Addressing Large-Scale Therapeutic Virus Production Using High Quality Grade PEI-based Transfection Reagents: PEIpro® product range
Mathieu Porte, Msc, Bioproduction Project Leader provides the latest news on how Polyplus-transfection® supports the fast-growing Gene Therapy field...Continued
Advanced CHO Transient Expression System Provides Increased Productivity and Efficiency
Transient transfection has been used for years to quickly and cost-effectively manufacture recombinant protein. The advantage of using transient transfection is that it takes significantly less time to produce proteins when compared with the alternative ... Continued
Transfection Reagent Portfolio Enables Seamless Scalability from R&D to Commercial Therapeutic Viral Vector Manufacturing
Cell and gene therapies are achieving greater success in the clinic and as a result there is an increasing need to transition manufacturing from research scale to clinical and ultimately to commercialization. Critical to the ... Continued
Increased CHO Transfection Efficiency and Production in a Straight Forward System
Transient protein production enables quick and efficient production of milligram to gram quantities of recombinant protein, which saves time and cost compared to developing a genetically stable cell line for use in bioproduction. This is ... Continued
PEIpro® Enables Seamless Scale-up of Transient Transfection for Therapeutic Viral Vector Manufacturing
With the launch of commercially available PEIpro®-GMP, Polyplus-transfection® SA now provides a complete PEIpro® product range to address concerns often raised with transient transfection for large scale manufacturing of viral vectors: efficiency, reproducibility and scalability....Continued